Serum SARS-COV-2 Nucleocapsid Protein: A Sensitivity and Specificity Early Diagnostic Marker for SARS-COV-2 Infection

To explore the diagnostic value of serum severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid (N) protein assay in the early stages of SARS-COV-2 infection. Serum N protein level in SARS-COV-2 infected patients and non-SARS-COV-2 infected population was measured by enzyme-linked...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in cellular and infection microbiology Vol. 10; p. 470
Main Authors Li, Tao, Wang, Li, Wang, Huihui, Li, Xuemei, Zhang, Shubing, Xu, Yuanhong, Wei, Wei
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 04.09.2020
Subjects
Online AccessGet full text

Cover

Loading…
Abstract To explore the diagnostic value of serum severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid (N) protein assay in the early stages of SARS-COV-2 infection. Serum N protein level in SARS-COV-2 infected patients and non-SARS-COV-2 infected population was measured by enzyme-linked immunosorbent assay (ELISA) double antibody sandwich assay. Colloidal gold immunochromatography assay was used to detect serum N protein antibodies in the above populations. Fifty cases of SARS-CoV-2 nucleic acid-positive and SARS-CoV-2 antibody-negative patients had a serum N protein positivity rate of 76%. Thirty-seven patients who were positive for serum SARS-CoV-2 antibody after infection had a serum SARS-CoV-2 N protein positivity rate of 2.7%. Serum N protein test results of 633 non-SARS-COV-2 infected patients, including pregnant women, patients with other respiratory infections, and individuals with increased rheumatoid factor were all negative, with serum N protein concentration <10.00 pg/mL at 100% specificity. Using SPSS 19.0 to calculate the receiver operating characteristic curve, the area under the curve was determined to be 0.9756 (95% confidence interval 0.9485-1.000, < 0.0001), and sensitivity and specificity were 92% (95% confidence interval 81.16-96.85%) and 96.84% (95% confidence interval 95.17-97.15%), respectively. The best CUT-OFF value was 1.850 pg/mL. The measurement of serum SARS-COV-2 N protein has a high diagnostic value for infected patients before the antibody appears and shortens the window period of serological diagnosis. It is recommended that the manufacturer establish two different CUT-OFF values according to the purpose of the application. One CUT-OFF value is used for the diagnosis of clinical SARS-COV-2 infection, and the other is used to screen out as many suspected cases as possible.
AbstractList To explore the diagnostic value of serum severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid (N) protein assay in the early stages of SARS-COV-2 infection. Serum N protein level in SARS-COV-2 infected patients and non-SARS-COV-2 infected population was measured by enzyme-linked immunosorbent assay (ELISA) double antibody sandwich assay. Colloidal gold immunochromatography assay was used to detect serum N protein antibodies in the above populations. Fifty cases of SARS-CoV-2 nucleic acid-positive and SARS-CoV-2 antibody-negative patients had a serum N protein positivity rate of 76%. Thirty-seven patients who were positive for serum SARS-CoV-2 antibody after infection had a serum SARS-CoV-2 N protein positivity rate of 2.7%. Serum N protein test results of 633 non-SARS-COV-2 infected patients, including pregnant women, patients with other respiratory infections, and individuals with increased rheumatoid factor were all negative, with serum N protein concentration <10.00 pg/mL at 100% specificity. Using SPSS 19.0 to calculate the receiver operating characteristic curve, the area under the curve was determined to be 0.9756 (95% confidence interval 0.9485-1.000, < 0.0001), and sensitivity and specificity were 92% (95% confidence interval 81.16-96.85%) and 96.84% (95% confidence interval 95.17-97.15%), respectively. The best CUT-OFF value was 1.850 pg/mL. The measurement of serum SARS-COV-2 N protein has a high diagnostic value for infected patients before the antibody appears and shortens the window period of serological diagnosis. It is recommended that the manufacturer establish two different CUT-OFF values according to the purpose of the application. One CUT-OFF value is used for the diagnosis of clinical SARS-COV-2 infection, and the other is used to screen out as many suspected cases as possible.
Objective: To explore the diagnostic value of serum severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid (N) protein assay in the early stages of SARS-COV-2 infection.Methods: Serum N protein level in SARS-COV-2 infected patients and non-SARS-COV-2 infected population was measured by enzyme-linked immunosorbent assay (ELISA) double antibody sandwich assay. Colloidal gold immunochromatography assay was used to detect serum N protein antibodies in the above populations.Results: Fifty cases of SARS-CoV-2 nucleic acid-positive and SARS-CoV-2 antibody-negative patients had a serum N protein positivity rate of 76%. Thirty-seven patients who were positive for serum SARS-CoV-2 antibody after infection had a serum SARS-CoV-2 N protein positivity rate of 2.7%. Serum N protein test results of 633 non-SARS-COV-2 infected patients, including pregnant women, patients with other respiratory infections, and individuals with increased rheumatoid factor were all negative, with serum N protein concentration <10.00 pg/mL at 100% specificity. Using SPSS 19.0 to calculate the receiver operating characteristic curve, the area under the curve was determined to be 0.9756 (95% confidence interval 0.9485–1.000, p < 0.0001), and sensitivity and specificity were 92% (95% confidence interval 81.16–96.85%) and 96.84% (95% confidence interval 95.17–97.15%), respectively. The best CUT-OFF value was 1.850 pg/mL.Conclusion: The measurement of serum SARS-COV-2 N protein has a high diagnostic value for infected patients before the antibody appears and shortens the window period of serological diagnosis. It is recommended that the manufacturer establish two different CUT-OFF values according to the purpose of the application. One CUT-OFF value is used for the diagnosis of clinical SARS-COV-2 infection, and the other is used to screen out as many suspected cases as possible.
Objective: To explore the diagnostic value of serum severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid (N) protein assay in the early stages of SARS-COV-2 infection. Methods: Serum N protein level in SARS-COV-2 infected patients and non-SARS-COV-2 infected population was measured by enzyme-linked immunosorbent assay (ELISA) double antibody sandwich assay. Colloidal gold immunochromatography assay was used to detect serum N protein antibodies in the above populations. Results: Fifty cases of SARS-CoV-2 nucleic acid-positive and SARS-CoV-2 antibody-negative patients had a serum N protein positivity rate of 76%. Thirty-seven patients who were positive for serum SARS-CoV-2 antibody after infection had a serum SARS-CoV-2 N protein positivity rate of 2.7%. Serum N protein test results of 633 non-SARS-COV-2 infected patients, including pregnant women, patients with other respiratory infections, and individuals with increased rheumatoid factor were all negative, with serum N protein concentration <10.00 pg/mL at 100% specificity. Using SPSS 19.0 to calculate the receiver operating characteristic curve, the area under the curve was determined to be 0.9756 (95% confidence interval 0.9485–1.000, p < 0.0001), and sensitivity and specificity were 92% (95% confidence interval 81.16–96.85%) and 96.84% (95% confidence interval 95.17–97.15%), respectively. The best CUT-OFF value was 1.850 pg/mL. Conclusion: The measurement of serum SARS-COV-2 N protein has a high diagnostic value for infected patients before the antibody appears and shortens the window period of serological diagnosis. It is recommended that the manufacturer establish two different CUT-OFF values according to the purpose of the application. One CUT-OFF value is used for the diagnosis of clinical SARS-COV-2 infection, and the other is used to screen out as many suspected cases as possible.
Objective: To explore the diagnostic value of serum severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid (N) protein assay in the early stages of SARS-COV-2 infection. Methods: Serum N protein level in SARS-COV-2 infected patients and non-SARS-COV-2 infected population was measured by enzyme-linked immunosorbent assay (ELISA) double antibody sandwich assay. Colloidal gold immunochromatography assay was used to detect serum N protein antibodies in the above populations. Results: Fifty cases of SARS-CoV-2 nucleic acid-positive and SARS-CoV-2 antibody-negative patients had a serum N protein positivity rate of 76%. Thirty-seven patients who were positive for serum SARS-CoV-2 antibody after infection had a serum SARS-CoV-2 N protein positivity rate of 2.7%. Serum N protein test results of 633 non-SARS-COV-2 infected patients, including pregnant women, patients with other respiratory infections, and individuals with increased rheumatoid factor were all negative, with serum N protein concentration <10.00 pg/mL at 100% specificity. Using SPSS 19.0 to calculate the receiver operating characteristic curve, the area under the curve was determined to be 0.9756 (95% confidence interval 0.9485-1.000, p < 0.0001), and sensitivity and specificity were 92% (95% confidence interval 81.16-96.85%) and 96.84% (95% confidence interval 95.17-97.15%), respectively. The best CUT-OFF value was 1.850 pg/mL. Conclusion: The measurement of serum SARS-COV-2 N protein has a high diagnostic value for infected patients before the antibody appears and shortens the window period of serological diagnosis. It is recommended that the manufacturer establish two different CUT-OFF values according to the purpose of the application. One CUT-OFF value is used for the diagnosis of clinical SARS-COV-2 infection, and the other is used to screen out as many suspected cases as possible.Objective: To explore the diagnostic value of serum severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid (N) protein assay in the early stages of SARS-COV-2 infection. Methods: Serum N protein level in SARS-COV-2 infected patients and non-SARS-COV-2 infected population was measured by enzyme-linked immunosorbent assay (ELISA) double antibody sandwich assay. Colloidal gold immunochromatography assay was used to detect serum N protein antibodies in the above populations. Results: Fifty cases of SARS-CoV-2 nucleic acid-positive and SARS-CoV-2 antibody-negative patients had a serum N protein positivity rate of 76%. Thirty-seven patients who were positive for serum SARS-CoV-2 antibody after infection had a serum SARS-CoV-2 N protein positivity rate of 2.7%. Serum N protein test results of 633 non-SARS-COV-2 infected patients, including pregnant women, patients with other respiratory infections, and individuals with increased rheumatoid factor were all negative, with serum N protein concentration <10.00 pg/mL at 100% specificity. Using SPSS 19.0 to calculate the receiver operating characteristic curve, the area under the curve was determined to be 0.9756 (95% confidence interval 0.9485-1.000, p < 0.0001), and sensitivity and specificity were 92% (95% confidence interval 81.16-96.85%) and 96.84% (95% confidence interval 95.17-97.15%), respectively. The best CUT-OFF value was 1.850 pg/mL. Conclusion: The measurement of serum SARS-COV-2 N protein has a high diagnostic value for infected patients before the antibody appears and shortens the window period of serological diagnosis. It is recommended that the manufacturer establish two different CUT-OFF values according to the purpose of the application. One CUT-OFF value is used for the diagnosis of clinical SARS-COV-2 infection, and the other is used to screen out as many suspected cases as possible.
Author Xu, Yuanhong
Li, Tao
Wang, Li
Wei, Wei
Zhang, Shubing
Li, Xuemei
Wang, Huihui
AuthorAffiliation 3 Biohit Healthcare (Hefei) Co., Ltd , Hefei , China
1 Department of Clinical Laboratory, The First Affiliated Hospital of Anhui Medical University , Hefei , China
2 Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, Anhui Anti-inflammatory and Immune Medicine Innovation Team, Institute of Clinical Pharmacology, Anhui Medical University , Hefei , China
AuthorAffiliation_xml – name: 3 Biohit Healthcare (Hefei) Co., Ltd , Hefei , China
– name: 1 Department of Clinical Laboratory, The First Affiliated Hospital of Anhui Medical University , Hefei , China
– name: 2 Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, Anhui Anti-inflammatory and Immune Medicine Innovation Team, Institute of Clinical Pharmacology, Anhui Medical University , Hefei , China
Author_xml – sequence: 1
  givenname: Tao
  surname: Li
  fullname: Li, Tao
– sequence: 2
  givenname: Li
  surname: Wang
  fullname: Wang, Li
– sequence: 3
  givenname: Huihui
  surname: Wang
  fullname: Wang, Huihui
– sequence: 4
  givenname: Xuemei
  surname: Li
  fullname: Li, Xuemei
– sequence: 5
  givenname: Shubing
  surname: Zhang
  fullname: Zhang, Shubing
– sequence: 6
  givenname: Yuanhong
  surname: Xu
  fullname: Xu, Yuanhong
– sequence: 7
  givenname: Wei
  surname: Wei
  fullname: Wei, Wei
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33014893$$D View this record in MEDLINE/PubMed
BookMark eNp1kk1v1DAQhi1UREvpnRPKkUsWf8SJwwFptRRYqVBEgKs1cSaLS2Jv7aTS_nuS3RZtkfBlxva8z1ie9zk5cd4hIS8ZXQihyjetsX294JTTBaVZQZ-QM86FTHmp1MlRfkouYryh0yooV6V4Rk6FoCyb0jMyVhjGPqmW36p0df0z5cmX0XToDWyjbZKvwQ9o3dtkmVTooh3snR12CbgmqbZobGvNvL-E0O2S9xY2zsfBmuQzhN8YktaHY_TatWgG690L8rSFLuLFfTwnPz5cfl99Sq-uP65Xy6vUSK6GVHDayBpk3kqUyEqsJTVQG5kDYJurXLJCNgb4FEpaM5MpBSiVKhiHErg4J-sDt_Fwo7fB9hB22oPV-wMfNhrC9N4ONRdQ8lpgWwqeNZzVjWkBKZUZy0ByObHeHVjbse6xMeiGAN0j6OMbZ3_pjb_TRVYqmc-A1_eA4G9HjIPubTTYdeDQj1HzLFO5kCxXU-mr415_mzzMbSrIDwUm-BgDtnqaA8xfO7W2nWZUzx7Re4_o2SN675FJSP8RPrD_K_kDc5i-5g
CitedBy_id crossref_primary_10_1002_jev2_12412
crossref_primary_10_1016_j_talanta_2024_126709
crossref_primary_10_1111_crj_13331
crossref_primary_10_7717_peerj_15515
crossref_primary_10_1093_ofid_ofae561
crossref_primary_10_1016_j_isci_2024_110177
crossref_primary_10_1021_acssynbio_0c00566
crossref_primary_10_1109_JSEN_2023_3274110
crossref_primary_10_12688_f1000research_122161_1
crossref_primary_10_1016_j_isci_2024_108976
crossref_primary_10_1016_j_trac_2024_117609
crossref_primary_10_12688_f1000research_122161_2
crossref_primary_10_1016_j_bios_2021_113922
crossref_primary_10_1021_acs_analchem_4c04225
crossref_primary_10_1097_IM9_0000000000000071
crossref_primary_10_3390_chemosensors10070287
crossref_primary_10_1016_j_ijbiomac_2024_129523
crossref_primary_10_1016_j_bios_2021_113160
crossref_primary_10_1017_S1431927621005134
crossref_primary_10_3390_v13061115
crossref_primary_10_1021_acs_analchem_1c04966
crossref_primary_10_3390_v14081653
crossref_primary_10_1016_j_isci_2023_105995
crossref_primary_10_1002_anie_202203662
crossref_primary_10_1021_acssensors_0c02561
crossref_primary_10_1093_ofid_ofad346
crossref_primary_10_1128_spectrum_03410_23
crossref_primary_10_3390_ijms231911589
crossref_primary_10_1038_s41467_021_26652_7
crossref_primary_10_3390_v14061141
crossref_primary_10_1021_acs_analchem_1c04296
crossref_primary_10_1039_D1AN01350E
crossref_primary_10_3389_fonc_2022_923467
crossref_primary_10_1021_acsomega_1c04012
crossref_primary_10_3390_bios11090310
crossref_primary_10_1093_clinchem_hvab148
crossref_primary_10_1128_JVI_01396_21
crossref_primary_10_1002_ange_202203662
crossref_primary_10_3390_diagnostics14060642
crossref_primary_10_3390_molecules28052104
crossref_primary_10_1093_ofid_ofac563
crossref_primary_10_1007_s00296_023_05489_x
crossref_primary_10_3390_microorganisms9112214
crossref_primary_10_1080_23744235_2024_2382263
crossref_primary_10_52396_JUSTC_2022_0020
crossref_primary_10_1016_j_bios_2021_113029
crossref_primary_10_3389_fimmu_2022_827146
crossref_primary_10_1021_acssensors_2c00317
crossref_primary_10_1016_j_aca_2023_341838
crossref_primary_10_1021_acssensors_3c01093
crossref_primary_10_1016_j_trac_2023_117473
crossref_primary_10_3390_diagnostics13091549
crossref_primary_10_1016_j_snb_2023_133331
crossref_primary_10_2217_fvl_2021_0211
crossref_primary_10_1128_JCM_01001_21
crossref_primary_10_1128_msphere_00067_23
crossref_primary_10_1002_smll_202301162
crossref_primary_10_3390_ijms24087174
crossref_primary_10_1016_j_snb_2021_130739
crossref_primary_10_1021_acscentsci_2c01263
crossref_primary_10_1007_s13404_023_00338_y
crossref_primary_10_1186_s12964_024_01665_z
crossref_primary_10_1093_infdis_jiac225
crossref_primary_10_3389_fmed_2021_615099
crossref_primary_10_1016_j_cca_2024_119951
crossref_primary_10_1186_s12985_023_01968_6
crossref_primary_10_1002_jmv_27520
crossref_primary_10_1021_acs_analchem_1c04470
crossref_primary_10_1186_s12951_021_01032_x
crossref_primary_10_1080_19420862_2021_1905978
crossref_primary_10_3390_vaccines10040516
crossref_primary_10_3389_fonc_2024_1346312
crossref_primary_10_3390_life12050649
crossref_primary_10_1515_rams_2023_0105
crossref_primary_10_3390_diagnostics12102427
crossref_primary_10_1002_14651858_CD013652_pub2
Cites_doi 10.1093/cid/ciaa489
10.1002/eji.202048715
10.1016/j.nmni.2020.100713
10.14293/S2199-1006.1.SOR-.PPA94RC.v1
10.1681/ASN.2020040432
10.1101/2020.05.24.20111849
10.1148/radiol.2020200343
10.2807/1560-7917.ES.2020.25.9.2000173
10.2807/1560-7917.ES.2020.25.3.2000045
10.3760/cma.j.cn112151-20200312-00193
10.1080/22221751.2020.1762515
10.1093/infdis/jiaa243
10.1128/JCM.00310-20
10.1021/acs.analchem.0c01975
10.2807/1560-7917.ES.2020.25.6.2000082
10.1016/S1473-3099(20)30196-1
10.2214/AJR.20.22959
10.1016/S0140-6736(20)30183-5
ContentType Journal Article
Copyright Copyright © 2020 Li, Wang, Wang, Li, Zhang, Xu and Wei.
Copyright © 2020 Li, Wang, Wang, Li, Zhang, Xu and Wei. 2020 Li, Wang, Wang, Li, Zhang, Xu and Wei
Copyright_xml – notice: Copyright © 2020 Li, Wang, Wang, Li, Zhang, Xu and Wei.
– notice: Copyright © 2020 Li, Wang, Wang, Li, Zhang, Xu and Wei. 2020 Li, Wang, Wang, Li, Zhang, Xu and Wei
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOA
DOI 10.3389/fcimb.2020.00470
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE


MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2235-2988
ExternalDocumentID oai_doaj_org_article_23a92b3ef9324d21bdcfae005414a525
PMC7498565
33014893
10_3389_fcimb_2020_00470
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Scientific Research Project of Anhui Medical University for the Prevention and Control of New Coronavirus Pneumonia
  grantid: YJGG202002
– fundername: Scientific Research Project of Anhui Province for the Prevention and Control of New Coronavirus Pneumonia
  grantid: 202004a07020015
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AENEX
AFPKN
AIAGR
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EMOBN
GROUPED_DOAJ
GX1
HYE
INR
KQ8
M48
M~E
OK1
PGMZT
RPM
CGR
CUY
CVF
ECM
EIF
IPNFZ
NPM
RIG
7X8
5PM
ID FETCH-LOGICAL-c528t-320d5ba56f5e5e19eb50cabc56aaef6865175dca217590b1c488ae588712a9a23
IEDL.DBID M48
ISSN 2235-2988
IngestDate Wed Aug 27 01:27:17 EDT 2025
Thu Aug 21 13:55:35 EDT 2025
Fri Jul 11 02:55:02 EDT 2025
Thu Apr 03 07:02:07 EDT 2025
Thu Apr 24 22:51:56 EDT 2025
Tue Jul 01 04:32:25 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords COVID-19
colloidal gold immunochromatography
nucleocapsid protein
SARS-CoV-2
diagnostic value
Language English
License Copyright © 2020 Li, Wang, Wang, Li, Zhang, Xu and Wei.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c528t-320d5ba56f5e5e19eb50cabc56aaef6865175dca217590b1c488ae588712a9a23
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
This article was submitted to Clinical Microbiology, a section of the journal Frontiers in Cellular and Infection Microbiology
Edited by: Alix Thérèse Coste, Centre Hospitalier Universitaire Vaudois (CHUV), Switzerland
Reviewed by: Brian Carey, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), United States; Riti Sharan, Texas Biomedical Research Institute, United States
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fcimb.2020.00470
PMID 33014893
PQID 2448635168
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_23a92b3ef9324d21bdcfae005414a525
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7498565
proquest_miscellaneous_2448635168
pubmed_primary_33014893
crossref_citationtrail_10_3389_fcimb_2020_00470
crossref_primary_10_3389_fcimb_2020_00470
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2020-09-04
PublicationDateYYYYMMDD 2020-09-04
PublicationDate_xml – month: 09
  year: 2020
  text: 2020-09-04
  day: 04
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in cellular and infection microbiology
PublicationTitleAlternate Front Cell Infect Microbiol
PublicationYear 2020
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References B10
B13
Qu (B14) 2020
Konrad (B11) 2020; 25
Li (B12) 2020
Tripathi (B19) 2020; 28
Sun (B17) 2020; 9
Zainol Rashid (B22) 2020; 42
Cai (B2) 2020
Xie (B20) 2020; 296
Abduljalil (B1) 2020; 36
Shen (B16) 2020; 12
Reusken (B15) 2020; 25
Chan (B3) 2020; 58
Grant (B7) 2020; 92
To (B18) 2020; 20
Corman (B5) 2020; 25
Farkash (B6) 2020; 31
Haljasmägi (B8) 2020
Huang (B9) 2020; 395
Yao (B21) 2020; 49
Cheng (B4) 2020; 215
References_xml – year: 2020
  ident: B14
  article-title: Profile of IgG and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
  publication-title: Clin. Infect. Dis
  doi: 10.1093/cid/ciaa489
– ident: B13
– ident: B10
– year: 2020
  ident: B8
  article-title: LIPS method for the detection of SARS-CoV-2 antibodies to spike and nucleocapsid proteins
  publication-title: Eur. J. Immunol.
  doi: 10.1002/eji.202048715
– volume: 36
  start-page: 100713
  year: 2020
  ident: B1
  article-title: Laboratory diagnosis of SARS-CoV-2: available approaches and limitations
  publication-title: N. Microb. N. Infect.
  doi: 10.1016/j.nmni.2020.100713
– volume: 28
  start-page: 18
  year: 2020
  ident: B19
  article-title: COVID 19 diagnostic multiplicity and its role in community surveillance and control
  publication-title: Infez. Med
  doi: 10.14293/S2199-1006.1.SOR-.PPA94RC.v1
– volume: 31
  start-page: 1683
  year: 2020
  ident: B6
  article-title: Ultrastructural evidence for direct renal infection with SARS-CoV-2
  publication-title: J. Am. Soc. Nephrol.
  doi: 10.1681/ASN.2020040432
– year: 2020
  ident: B12
  article-title: Serum SARS-COV-2 nucleocapsid protein:a sensitivity and specificity early diagnostic marker for SARS-COV-2 infection
  publication-title: MedRxiv.
  doi: 10.1101/2020.05.24.20111849
– volume: 296
  start-page: E41
  year: 2020
  ident: B20
  article-title: Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT-PCR testing
  publication-title: Radiology
  doi: 10.1148/radiol.2020200343
– volume: 25
  start-page: 2000173
  year: 2020
  ident: B11
  article-title: Rapid establishment of laboratory diagnostics for the novel coronavirus SARS-CoV-2 in Bavaria, Germany, February 2020
  publication-title: Euro Surveill
  doi: 10.2807/1560-7917.ES.2020.25.9.2000173
– volume: 25
  start-page: 2000045
  year: 2020
  ident: B5
  article-title: Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
  publication-title: Euro Surveill
  doi: 10.2807/1560-7917.ES.2020.25.3.2000045
– volume: 49
  start-page: 411
  year: 2020
  ident: B21
  article-title: A pathological report of three COVID-19 cases by minimally invasive autopsies
  publication-title: Zhonghua Bing Li Xue Za Zhi
  doi: 10.3760/cma.j.cn112151-20200312-00193
– volume: 9
  start-page: 940
  year: 2020
  ident: B17
  article-title: Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients
  publication-title: Emerg. Microbes Infect
  doi: 10.1080/22221751.2020.1762515
– year: 2020
  ident: B2
  article-title: A peptide-based magnetic chemiluminescence enzyme immunoassay for serological diagnosis of coronavirus disease 2019 (COVID-19)
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jiaa243
– volume: 42
  start-page: 13
  year: 2020
  ident: B22
  article-title: Diagnostic performance of COVID-19 serology assays
  publication-title: Malays. J. Pathol.
– volume: 58
  start-page: e00310
  year: 2020
  ident: B3
  article-title: Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-polymerase chain reaction assay validated in vitro and with clinical specimens
  publication-title: J. Clin. Microbiol.
  doi: 10.1128/JCM.00310-20
– volume: 92
  start-page: 11305
  year: 2020
  ident: B7
  article-title: A SARS-CoV-2 coronavirus nucleocapsid antigen-detecting half-strip lateral flow assay towards the development of point of care tests using commercially available reagents
  publication-title: Anal Chem.
  doi: 10.1021/acs.analchem.0c01975
– volume: 12
  start-page: 1348
  year: 2020
  ident: B16
  article-title: Clinical evaluation of a rapid colloidal gold immunochromatography assay for SARS-Cov-2 IgM/IgG
  publication-title: Am. J. Transl. Res.
– volume: 25
  start-page: 2000082
  year: 2020
  ident: B15
  article-title: Laboratory readiness and response for novel coronavirus (2019-nCoV) in expert laboratories in 30 EU/EEA countries, January 2020
  publication-title: Euro Surveill
  doi: 10.2807/1560-7917.ES.2020.25.6.2000082
– volume: 20
  start-page: 565
  year: 2020
  ident: B18
  article-title: Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study
  publication-title: Lancet Infect. Dis
  doi: 10.1016/S1473-3099(20)30196-1
– volume: 215
  start-page: 121
  year: 2020
  ident: B4
  article-title: Clinical features and chest CT manifestations of coronavirus disease 2019 (COVID-19) in a single-center study in Shanghai, China
  publication-title: Am. J. Roentgenol
  doi: 10.2214/AJR.20.22959
– volume: 395
  start-page: 497
  year: 2020
  ident: B9
  article-title: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)30183-5
SSID ssj0000702893
Score 2.4907858
Snippet To explore the diagnostic value of serum severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid (N) protein assay in the early stages of...
Objective: To explore the diagnostic value of serum severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid (N) protein assay in the early...
Objective: To explore the diagnostic value of serum severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid (N) protein assay in the early...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 470
SubjectTerms Antibodies, Viral - blood
Betacoronavirus - isolation & purification
Biomarkers - blood
Cellular and Infection Microbiology
Clinical Laboratory Techniques - methods
colloidal gold immunochromatography
Coronavirus Infections - blood
Coronavirus Infections - diagnosis
Coronavirus Nucleocapsid Proteins
COVID-19
COVID-19 Testing
diagnostic value
Enzyme-Linked Immunosorbent Assay - methods
Female
Humans
Male
nucleocapsid protein
Nucleocapsid Proteins - blood
Pandemics
Phosphoproteins
Pneumonia, Viral - blood
Pneumonia, Viral - diagnosis
Pregnancy
SARS-CoV-2
Sensitivity and Specificity
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1NT9wwELUqJKReUKEfBAoyUi8col07cWL3tkARIJWibqm4WbYzUVcqAcHuof--M3ZYZauqXHpM4tiWZ8bzRh6_YeyDhrEBGVSuITR5iRqMNtc2eYGbZTDBVSLQfefPl9XZdXlxo24Gpb4oJyzRA6eFG8nCGekLaBFolI0UvgmtA0IaonRKRvZS9HmDYCruwTWdoBXpXBKjMDNqw-zWYzwoKZWrpNrEAz8U6fr_hjH_TJUc-J7TV2yjB418kia7yV5At8XWUxnJX6_ZAg1-ccunk6_T_PjL91zyS2IpRi91j7rGr4iKYdZ95BM-pXT1VC-Cu67hsfo8cUjgc6Q65icp9Q4H4nSNBx44otph1-d99lb3hl2ffvp2fJb35RTyoKSe54UcN8o7VbUKFAgDXo2D80FVzkFb6UohlGiCwyBFmbEXAW3bgcJdSEhnnCzesrXuroNtxjHmMVBj6NI2pqy18pUT2KP3GqBWTmRs9LS4NvRc41Ty4qfFmIPEYaM4LInDRnFk7HD5x33i2fhH2yOS17IdMWTHF6g3ttcb-5zeZOzgSdoWLYqOSVwHd4tHi4BHIwwTlc7YuyT95VAFRaCoWBmrV_RiZS6rX7rZj8jaXZdGI3re-R-T32UvaTlirlv5nq3NHxawh-Bo7vejHfwGeI4MtQ
  priority: 102
  providerName: Directory of Open Access Journals
Title Serum SARS-COV-2 Nucleocapsid Protein: A Sensitivity and Specificity Early Diagnostic Marker for SARS-COV-2 Infection
URI https://www.ncbi.nlm.nih.gov/pubmed/33014893
https://www.proquest.com/docview/2448635168
https://pubmed.ncbi.nlm.nih.gov/PMC7498565
https://doaj.org/article/23a92b3ef9324d21bdcfae005414a525
Volume 10
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fb9MwELbQ0NBeEIwfC4zJSLzwEFY7cWIjTaj7pYG0gShFe7Ns5wKVtnR0rcT-e-6ctKxT4TFN4rS5O9_31efvGHujoWdABpVqCFWaowdjzNVVmuFkGUxwhQi03_n0rDgZ5p_O1fnf7dHdC7xeSe2on9RwcvHu96-bDxjwe8Q4Md_u1mF06ZHqSarSyksk8PcxL5XUz-C0A_txXi5pVS1r1ypX3rjBHmREMbTJltJUVPNfBUHvVlLeSk3Hj9jDDlPyfusEj9k9aDbZettl8uYJm-F8MLvkg_7XQXrw-Xsq-RmJGGMSu0JX5F9IqWHUvOd9PqBq9radBHdNxWNzepKYwOOohMwP28o8fBCnXT4w4Qh6bw_9sSvuap6y4fHRt4OTtOu2kAYl9TTNZK9S3qmiVqBAGPCqF5wPqnAO6kIXCpFGFRxyGGV6XgQMfQcKJykhnXEye8bWmnEDW4wjJTJQIrOpK5OXWvnCCRzRew1QKicStjt_uTZ0UuTUEePCIiUhy9hoGUuWsdEyCXu7uOOqleH4z7X7ZK_FdSSgHT8YT37YLh6tzJyRPoMa8WteSeGrUDsgACtyp6RK2Ou5tS0GHK2iuAbGs2uLeEgjShOFTtjz1vqLR829J2Hlkl8sfZflM83oZxT1LnOjEVy_-OeYL9kG_cZY35Zvs7XpZAavEBBN_U78I2EnevsfdNUImA
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Serum+SARS-COV-2+Nucleocapsid+Protein%3A+A+Sensitivity+and+Specificity+Early+Diagnostic+Marker+for+SARS-COV-2+Infection&rft.jtitle=Frontiers+in+cellular+and+infection+microbiology&rft.au=Li%2C+Tao&rft.au=Wang%2C+Li&rft.au=Wang%2C+Huihui&rft.au=Li%2C+Xuemei&rft.date=2020-09-04&rft.eissn=2235-2988&rft.volume=10&rft.spage=470&rft_id=info:doi/10.3389%2Ffcimb.2020.00470&rft_id=info%3Apmid%2F33014893&rft.externalDocID=33014893
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2235-2988&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2235-2988&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2235-2988&client=summon